Key result
HCM is linked to an ~83% higher risk of 30-day major events after non-cardiac surgery.
Why the study?
Does the presence of hypertrophic cardiomyopathy increase the risk of 30-day composite adverse events in patients undergoing intermediate-risk and high-risk non-cardiac surgery?
Cohort (n=276)
No
Does the presence of hypertrophic cardiomyopathy increase the risk of 30-day composite adverse events in patients undergoing intermediate-risk and high-risk non-cardiac surgery?
Patients with hypertrophic cardiomyopathy undergoing intermediate-to-high risk non-cardiac surgery have a higher risk of 30-day composite adverse events compared to matched controls, primarily driven by decompensated heart failure.
Answers are grounded in this paper and cite their sources.
May warrant enhanced perioperative monitoring in HCM; leaves open whether risk is modifiable by targeted strategies.
OBJECTIVE: Due to their unique pathophysiological profile, patients with hypertrophic cardiomyopathy (HCM) undergoing non-cardiac surgery require additional attention to perioperative management. We sought to compare perioperative outcomes of patients with HCM undergoing non-cardiac surgery with a matched group patients without HCM. METHODS: This observational cohort study conducted at a tertiary care centre included patients with HCM (n=92, age 67 years, 54% men) undergoing intermediate-risk and high-risk non-cardiac surgeries between 1/2007 and 12/2013 (excluding <18 years, prior septal myectomy/alcohol ablation, low-risk surgery) who were 1:2 matched (based on age, gender, type and time of non-cardiac surgery) with patients without HCM (n=184, median age 65 years, 53% men). A composite endpoint (30-day postoperative death, myocardial infarction, stroke, in-hospital decompensated congestive heart failure (CHF) and rehospitalisation within 30 days) and postoperative atrial fibrillation (AF) were recorded. RESULTS: There was a significantly lower incidence of intraoperative hypotension/tachycardia in patients with HCM versus those without HCM (p<0.001). At 30 days postoperatively, 42 (15%) patients had composite events. Rates of 30-day death, MI or stroke were very low in patients with HCM (5%). However, a significantly higher proportion of patients with HCM met the composite endpoint versus patients without HCM (20 (22%) vs 22 (12%), p=0.03), driven by decompensated CHF. On logistic regression, HCM, high-risk non-cardiac surgery, high anaesthesia risk score and intraoperative duration of hypotension were independently associated with 30-day composite events (p<0.05). CONCLUSIONS: Patients with HCM undergoing high-risk and intermediate-risk non-cardiac surgeries have a low perioperative event rate, at an experienced centre. However, they have a higher risk of composite events versus matched patients without HCM.
No takes yet. Share an insight, caveat, or question.
Dhillon et al. (2016) conducted a cohort in Hypertrophic cardiomyopathy (n=276). Hypertrophic cardiomyopathy vs. Matched patients without HCM was evaluated on Composite of 30-day postoperative death, myocardial infarction, stroke, in-hospital decompensated congestive heart failure and rehospitalisation within 30 days (p=0.03). Hypertrophic cardiomyopathy in patients undergoing non-cardiac surgery was associated with a higher risk of 30-day composite events compared to matched patients without HCM (22% vs 12%, p=0.03).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: